🔗 Share this article Individuals Stopping Weight-Loss Medications Gain Back Weight at a Quadrupled Rate Than People Using Diet and Exercise Obesity treatment involves ongoing approaches. A recent study reveals that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who stop traditional lifestyle programs. Findings released in a major health publication shows that while overweight people frequently drop a large proportion of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation. "People using such medications need to be aware of the risk of fast weight regain when the treatment is stopped," stated expert Dr. Susan Jebb. This pace of recovery suggests a reversion to starting mass within about 18 months. Comparing Treatments The analysis, which examined dozens of studies involving thousands of patients, compared the results of the injectable medications with conventional dieting. The team note that people who lose weight through diet and exercise generally see a slower creep back—around 100 grams monthly—post-intervention. Explaining the Quick Rebound Experts believe the way of the injections explains the heightened weight return. The injections copy a body's own chemical called GLP-1, which helps regulate hunger. "Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist. "Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating much more probable." A Lifelong Disease? Health authorities recommend the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications. A number of clinicians contend that, considering the significant potential of relapse, the treatment is often life-long. This view is reinforced by drug manufacturers, who note that the findings "underscore the persistent character of excess weight," akin to managing diseases like high blood pressure. Patient Experiences Users who have come off the jabs explain a intense return of hunger. "I experienced a switch that goes on and you're instantly extremely hungry," described an individual. The struggle is exacerbated if users have not adopted permanent dietary or behavioural changes during treatment. Significant Use Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with demand being substantial. Adoption is greater among females than males. The 40s and 50s age group shows the highest usage rates. A large proportion obtain the drugs through private prescriptions rather than the NHS. Finally, clinicians emphasize that while the jabs are powerful agents for weight loss, they are not a permanent cure and lasting health benefits hinges on ongoing lifestyle management.
Obesity treatment involves ongoing approaches. A recent study reveals that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who stop traditional lifestyle programs. Findings released in a major health publication shows that while overweight people frequently drop a large proportion of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation. "People using such medications need to be aware of the risk of fast weight regain when the treatment is stopped," stated expert Dr. Susan Jebb. This pace of recovery suggests a reversion to starting mass within about 18 months. Comparing Treatments The analysis, which examined dozens of studies involving thousands of patients, compared the results of the injectable medications with conventional dieting. The team note that people who lose weight through diet and exercise generally see a slower creep back—around 100 grams monthly—post-intervention. Explaining the Quick Rebound Experts believe the way of the injections explains the heightened weight return. The injections copy a body's own chemical called GLP-1, which helps regulate hunger. "Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist. "Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating much more probable." A Lifelong Disease? Health authorities recommend the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications. A number of clinicians contend that, considering the significant potential of relapse, the treatment is often life-long. This view is reinforced by drug manufacturers, who note that the findings "underscore the persistent character of excess weight," akin to managing diseases like high blood pressure. Patient Experiences Users who have come off the jabs explain a intense return of hunger. "I experienced a switch that goes on and you're instantly extremely hungry," described an individual. The struggle is exacerbated if users have not adopted permanent dietary or behavioural changes during treatment. Significant Use Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with demand being substantial. Adoption is greater among females than males. The 40s and 50s age group shows the highest usage rates. A large proportion obtain the drugs through private prescriptions rather than the NHS. Finally, clinicians emphasize that while the jabs are powerful agents for weight loss, they are not a permanent cure and lasting health benefits hinges on ongoing lifestyle management.